ZA200610578B - Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy - Google Patents

Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy

Info

Publication number
ZA200610578B
ZA200610578B ZA200610578A ZA200610578A ZA200610578B ZA 200610578 B ZA200610578 B ZA 200610578B ZA 200610578 A ZA200610578 A ZA 200610578A ZA 200610578 A ZA200610578 A ZA 200610578A ZA 200610578 B ZA200610578 B ZA 200610578B
Authority
ZA
South Africa
Prior art keywords
upar
upa
urokinase
diagnosis
receptor
Prior art date
Application number
ZA200610578A
Other languages
English (en)
Inventor
Graham C Parry
Andrew P Mazar
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of ZA200610578B publication Critical patent/ZA200610578B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
ZA200610578A 2004-05-25 2005-05-25 Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy ZA200610578B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57389604P 2004-05-25 2004-05-25

Publications (1)

Publication Number Publication Date
ZA200610578B true ZA200610578B (en) 2009-09-30

Family

ID=35451457

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610578A ZA200610578B (en) 2004-05-25 2005-05-25 Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy

Country Status (16)

Country Link
US (1) US8101726B2 (ja)
EP (1) EP1765397B1 (ja)
JP (1) JP4890449B2 (ja)
KR (1) KR20070047246A (ja)
CN (1) CN101022830A (ja)
AU (1) AU2005248400A1 (ja)
CA (1) CA2568428C (ja)
DK (1) DK1765397T3 (ja)
ES (1) ES2398221T3 (ja)
IL (1) IL179565A0 (ja)
MX (1) MXPA06013709A (ja)
PL (1) PL1765397T3 (ja)
PT (1) PT1765397E (ja)
RU (1) RU2006145905A (ja)
WO (1) WO2005116077A2 (ja)
ZA (1) ZA200610578B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343489B2 (en) * 2006-03-21 2013-01-01 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP5637855B2 (ja) * 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
CA2779958A1 (en) * 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2012085076A1 (en) 2010-12-22 2012-06-28 Ifom Fondazione Istituto Firc Di Oncologia Molecolare uPAR-ANTAGONISTS AND USES THEREOF
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
US9867923B2 (en) 2011-05-09 2018-01-16 University Of Miami Reducing soluble urokinase receptor in the circulation
US20140161803A1 (en) 2011-08-05 2014-06-12 IFOM Fondazione Istituo FIRC di Oncologia Molecolare Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
AU2014233055B2 (en) * 2013-03-15 2018-08-09 Board Of Regents, The University Of Texas System Inhibition of pulmonary fibrosis with nutlin-3a and peptides
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US10681506B1 (en) 2018-04-19 2020-06-09 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
US10959062B1 (en) 2018-04-19 2021-03-23 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
JP7496826B2 (ja) 2018-09-10 2024-06-07 ラング セラピューティクス，エルエルシー Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
JP2022513317A (ja) * 2018-09-28 2022-02-07 ヨッヘン ライザー ｓｕＰＡＲならびに急性腎傷害の予測および治療
AU2022276433A1 (en) * 2021-05-21 2023-12-07 Monopar Therapeutics Inc. Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use
AU2022287975A1 (en) * 2021-06-11 2023-12-14 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting upar and uses thereof
WO2023183667A1 (en) * 2022-03-24 2023-09-28 The United States Government As Representative By The Department Of Veterans Affairs Urokinase-type plasminogen activator receptor binding peptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
DE10117381A1 (de) * 2001-04-06 2002-10-10 Wilex Biotechnology Gmbh Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke
WO2003079974A2 (en) * 2002-03-18 2003-10-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Integrin ligand
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope

Also Published As

Publication number Publication date
WO2005116077A2 (en) 2005-12-08
PL1765397T3 (pl) 2013-04-30
MXPA06013709A (es) 2008-01-16
PT1765397E (pt) 2013-02-04
JP2008509086A (ja) 2008-03-27
CN101022830A (zh) 2007-08-22
AU2005248400A1 (en) 2005-12-08
EP1765397A4 (en) 2009-05-13
IL179565A0 (en) 2007-05-15
DK1765397T3 (da) 2013-02-04
ES2398221T3 (es) 2013-03-14
US8101726B2 (en) 2012-01-24
CA2568428C (en) 2020-12-29
CA2568428A1 (en) 2005-12-08
EP1765397B1 (en) 2012-10-24
WO2005116077A3 (en) 2005-12-29
KR20070047246A (ko) 2007-05-04
RU2006145905A (ru) 2008-06-27
EP1765397A2 (en) 2007-03-28
JP4890449B2 (ja) 2012-03-07
US20090180952A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
ZA200610578B (en) Ligands binding the complex of urokinase-type plasminogen activator (UPA) and its receptor (UPAR) that inhibit downstream upar interactions: Identification and use in diagnosis or therapy
EP1747522A4 (en) METHODS AND SYSTEMS FOR ENSURING GUARANTEED COMMERCIAL TRANSACTIONS
ZA200702421B (en) Iron complex for use in the treatment and/or prevention of nutritional disorders
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
GB0523576D0 (en) Drug composition and its use in therapy
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
EP1587944A4 (en) KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
PT2532679T (pt) Anticorpos humanos contra il13 e utilizações terapêuticas
WO2008073312A3 (en) Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
SI2486941T1 (sl) Humana protitelesa, ki vežejo CXCR4 in njihova uporaba
EP1572724A4 (en) KDR AND VEGF / KDR BINDING SPEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY
EP1773880A4 (en) ENV POLYPEPTIDE COMPLEXES AND METHOD FOR THEIR USE
EP2112902A4 (en) METHOD AND MEANS FOR MEASURING THE SYSTOLIC BLOOD PRESSURE IN THE FOOT CONTROL
WO2008125116A3 (en) Upar inhibition
EP1781685A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS
AU2003227148A8 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
EP1944039A4 (en) ACTIVE AGENT FOR THE TREATMENT OF TUMORS AND ITS USE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS
EP1997487A4 (en) PRODUCT USED IN THE PREVENTION AND TREATMENT OF CARDIAC DISEASES, CANCER AND INFLAMMATORY DISEASES
EP1807067A4 (en) SPHINGOSINKINASE ACTIVATOR AND TREATMENT AGENT FOR SKIN DISEASES THEREWITH
HK1130209A1 (en) Therapeutic and/or ameliorating agent for disseminated intravascular coagulation
GB201020621D0 (en) Pin for hygienic and/or medical use in the anal region
SI1639013T1 (sl) Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
EP1666046A4 (en) USE OF N-ACETYL-D-AMINOGLYCOSAMINE FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CANCER AND METASTASES
WO2007134274A3 (en) Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy